BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…
Don Wright, who recently finished his 100th marathon while on active treatment for multiple myeloma, will continue running, but now with the support of the…
Multiple myeloma patients undergoing autologous stem cell transplants (ASCT) may strongly benefit from SELLAS‘ WT-1 cancer vaccine, galinpepimut-S, according to recent data from a…
GlycoMimetics will present preclinical research at the American Association for Cancer Research (AACR) Annual Meeting 2017, demonstrating the potential of two drug candidates,…
